Re: Farmas USA
HZNP
Perspectivas 2018 mejores que 2017 según propio guidance de la compañía
Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments
-- Increases KRYSTEXXA® (pegloticase injection) Estimated Peak Annual Net Sales to more than $750 Million --
-- Increases Teprotumumab Estimated Peak Annual Net Sales to more than $750 Million --
-- Confirms Expectation of more than 50 Percent Year-Over-Year Net Sales Growth for KRYSTEXXA in 2018 --
-- Announces Licensing Agreement with MedImmune for Potential Next-Generation Biologic for Uncontrolled Gout --